Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

LABA-ICS Combo Boosts Survival in COPD With Cardiac Disease Risk

Key clinical point: Patients with chronic obstructive pulmonary disease (COPD) and either established cardiovascular disease or a high risk of an index cardiovascular event are more likely to survive if they take long-acting beta agonists/inhaled corticosteroids (LABA-ICS) vs. LABA alone.

Major finding: Over 13 years, patients on LABA-ICS were more likely to survive vs. LABA (hazard ratio 0.82, 95% CI 0.71–0.95, P = .007).

Study details: Population-based longitudinal propensity score-matched cohort study of new users of LABA-ICS (2,687) vs. LABA alone (2,687).

Disclosures: Imperial College London funded the study. The study authors report no relevant disclosures.


Patel HC et al. Int J Cardiol. 2019 Nov 26